
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Dec 25, 2025 02:04 am UTC| Business Health
French pharmaceutical giant Sanofi has announced plans to acquire U.S.-based biotech company Dynavax Technologies in a deal valued at approximately $2.2 billion (1.9 billion). The acquisition, agreed on Wednesday, is aimed...

GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Dec 25, 2025 01:49 am UTC| Health Business
Packaged food manufacturers and fast-food restaurants are preparing for major shifts in consumer demand as appetite-suppressing GLP-1 weight loss pills are expected to enter the U.S. market in early 2025. Analysts believe...

Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Dec 24, 2025 11:06 am UTC| Business Health
Sanofi has announced an agreement to acquire U.S.-based vaccines company Dynavax Technologies in an all-cash transaction valued at approximately $2.2 billion, marking another strategic move to expand its vaccines business....

FDA Approves Mitapivat for Anemia in Thalassemia Patients
Dec 24, 2025 05:24 am UTC| Governance Business Health
Agios Pharmaceuticals has announced a major regulatory milestone with the U.S. Food and Drug Administration approving mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia. The approval represents...

Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Dec 24, 2025 03:42 am UTC| Business Health
Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity drug market as they race to secure dominance before lower-cost generic alternatives arrive in early...

Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Dec 23, 2025 01:57 am UTC| Business Health
Novo Nordisk A/S (NYSE: NVO) shares jumped nearly 8% in after-hours trading on Monday following a major regulatory milestone: the U.S. Food and Drug Administration approved the companys Wegovy pill, making it the first...

AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Dec 22, 2025 07:39 am UTC| Business Health
AstraZeneca PLC (NASDAQ: AZN) announced on Monday that its Phase III LATIFY clinical trial evaluating ceralasertib in non-small cell lung cancer (NSCLC) did not achieve its primary endpoint. The late-stage study assessed...